What the experiment compared
After polyp removal, 1,108 participants were randomized to berberine or placebo. The main analysis included 891 with treatment exposure and available efficacy data, with planned colonoscopy follow-up through two years. [1]
Recurrent adenomas occurred less often in the berberine group. No colorectal cancers were detected during follow-up, so the trial could not establish a between-group reduction in cancer incidence. [1]
Interpretation and limits
The National Natural Science Foundation of China funded the study; conflicts were not established from the abstract. The reduced analysis population and precursor-lesion endpoint limit interpretation. These findings do not justify replacing colonoscopy surveillance or cancer treatment. [1]
A hypothetical distinction
Imagine a study reduces recurrence of a precursor lesion but observes no cancers in either group. It answers the lesion question while leaving the cancer-outcome comparison unresolved.
| Detail | Interpretation |
|---|---|
| After polypectomy | Prevention setting |
| Adenoma recurrence | Measured endpoint |
| Existing cancer | Not treated in this trial |
Sources for this article
- Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study - PubMed
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.